Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

The AlloHeme test can be used to predict relapse after allogeneic HCT in patients with AML or MDS, data suggest.

Google has revised the webpage for its Responsible AI and Human-Centered Technology (RAI-HCT) team, removing specific ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

76% of patients had HCT-CI ≤3; 65% of patients received reduced-intensity conditioning; 53% had CR, whereas 47% had stable disease at the time of transplant and 88% of patients had intermediate-risk ...

The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is excited to announce its ...

H.H. Sheikh Theyab bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Development and Fallen Heroes’ Affairs, has attended a ceremony for students graduating with ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...